[go: up one dir, main page]

MX2009003080A - Compuestos organicos heterociclicos. - Google Patents

Compuestos organicos heterociclicos.

Info

Publication number
MX2009003080A
MX2009003080A MX2009003080A MX2009003080A MX2009003080A MX 2009003080 A MX2009003080 A MX 2009003080A MX 2009003080 A MX2009003080 A MX 2009003080A MX 2009003080 A MX2009003080 A MX 2009003080A MX 2009003080 A MX2009003080 A MX 2009003080A
Authority
MX
Mexico
Prior art keywords
organic compounds
heterocyclic organic
stearoyl
modulate
derivatives
Prior art date
Application number
MX2009003080A
Other languages
English (en)
Inventor
Rajender Kamboj
Serguei Sviridov
Shaoyi Sun
Zaihui Zhang
Natalia Pokrovskaia
Natalie Dales
Jianmin Fu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009003080A publication Critical patent/MX2009003080A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud proporciona compuestos de la fórmula (I) que modulan la actividad de desaturasa de estearoil-CoA. Los métodos para utilizar estos derivados para modular la actividad de desaturasa de estearoil-CoA y las composiciones farmacéuticas que comprenden dichos derivados también están comprendidas.
MX2009003080A 2006-09-22 2007-09-19 Compuestos organicos heterociclicos. MX2009003080A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82662706P 2006-09-22 2006-09-22
PCT/US2007/078854 WO2008036715A1 (en) 2006-09-22 2007-09-19 Heterocyclic organic compounds

Publications (1)

Publication Number Publication Date
MX2009003080A true MX2009003080A (es) 2009-04-02

Family

ID=38962856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003080A MX2009003080A (es) 2006-09-22 2007-09-19 Compuestos organicos heterociclicos.

Country Status (11)

Country Link
US (1) US8236835B2 (es)
EP (1) EP2066664A1 (es)
JP (1) JP5351025B2 (es)
KR (1) KR20090053923A (es)
CN (1) CN101516877B (es)
AU (1) AU2007299870A1 (es)
BR (1) BRPI0718509A2 (es)
CA (1) CA2662574A1 (es)
MX (1) MX2009003080A (es)
RU (1) RU2009114857A (es)
WO (1) WO2008036715A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598548A (en) * 2006-08-15 2013-09-27 Novartis Ag Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
JP2010513403A (ja) 2006-12-20 2010-04-30 ノバルティス アーゲー Ｓｃｄ阻害剤としての２−置換５員ヘテロ環
WO2008106128A2 (en) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
ATE554078T1 (de) 2007-07-26 2012-05-15 Vitae Pharmaceuticals Inc Synthese von 11-beta-hydroxysteroid-dehydrogenase-1-hemmern
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
EP2229368A1 (en) 2007-12-11 2010-09-22 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW200934490A (en) 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (en) 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2714532A1 (en) 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
JP5730021B2 (ja) 2008-02-15 2015-06-03 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
AU2009216769A1 (en) 2008-02-20 2009-08-27 Novartis Ag Heterocyclic inhibitors of stearoyl-CoA desaturase
WO2009134392A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5451752B2 (ja) 2008-05-01 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ588954A (en) 2008-05-01 2012-08-31 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
PL2324018T3 (pl) 2008-07-25 2014-02-28 Boehringer Ingelheim Int Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
AU2010215035B2 (en) 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
KR20120080226A (ko) * 2009-10-01 2012-07-16 제논 파마슈티칼스 인크. 스테아로일-ｃｏａ 탈포화화효소를 조절하는 피라졸 유도체
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
KR20130137628A (ko) 2010-11-02 2013-12-17 베링거 인겔하임 인터내셔날 게엠베하 대사 장애를 치료하기 위한 약제학적 병용물
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
EP2852387A2 (en) 2012-05-22 2015-04-01 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
CA3032996C (en) * 2016-08-24 2025-05-06 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2018205275B2 (en) 2017-01-06 2024-05-02 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
CN108003086B (zh) * 2017-11-15 2020-08-14 宁波大学 一种3-胺基-2-吲哚酮类化合物的制备方法
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056208A (en) * 1933-01-21 1936-10-06 Earl B Putt Acetyl-salicylic acid composition
FR2123206A1 (en) * 1971-01-29 1972-09-08 Anvar Thiazolyl-pyrrolidinones - as analgesics, sedatives barbiturate-potentiators
US4659726A (en) 1984-04-19 1987-04-21 Kanebo, Ltd. Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
JPH02160783A (ja) * 1988-12-15 1990-06-20 Nippon Tokushu Noyaku Seizo Kk ３，４−ジメチル−ピロリジン誘導体及び除草剤
JPH04247076A (ja) 1991-02-01 1992-09-03 Canon Inc 液晶性化合物、これを含む液晶組成物、およびその使用方法、それを使用した液晶素子、表示装置
IT1254199B (it) 1992-02-06 1995-09-14 Ministero Dell Uni E Della Tiazolilpirroli ad attivita' fungicida
US5254576A (en) * 1992-04-03 1993-10-19 Bristol-Myers Squibb Company Diphenyl-heterocyclic-oxazole as platelet aggregation inhibitors
BR9507838A (pt) 1994-06-02 1997-09-16 Zeneca Ltd Composto processo para preparar o mesmo composição herbicida e processo para danificar severamente ou exterminar plantas não-desejadas
IT1271026B (it) * 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
GB9510744D0 (en) * 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
WO1998054164A1 (en) 1997-05-30 1998-12-03 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
WO2000006085A2 (en) 1998-07-28 2000-02-10 Smithkline Beecham Corporation Compounds and methods
WO2000034255A1 (en) 1998-12-04 2000-06-15 Ontogen Corporation Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin
JP2002539217A (ja) 1999-03-15 2002-11-19 アボット・ラボラトリーズ 抗菌活性を有する６−ｏ−置換マクロライド
US6054435A (en) * 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
CA2423251A1 (en) 2000-09-29 2002-04-04 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
CZ20031751A3 (cs) 2000-12-21 2004-03-17 Glaxo Group Limited Makrolidy
SK287900B6 (sk) * 2001-02-02 2012-03-02 Bristol-Myers Squibb Company Substituted azaindolexoacetic piperazine derivatives and pharmaceutical composition containing thereof
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
EP2272813B1 (en) * 2001-04-24 2016-11-16 Massachusetts Institute of Technology (MIT) Copper-catalyzed formation of carbon-oxygen bonds
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
AR036663A1 (es) 2001-10-01 2004-09-22 Bristol Myers Squibb Co Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios, las composiciones farmaceuticas que las contienen y los intermediarios para preparar dichos compuestos
GB0130705D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Chemical compounds
GB0208579D0 (en) 2002-04-13 2002-05-22 British Biotech Pharm Antibacterial agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
CA2504320A1 (en) * 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
US20050113423A1 (en) 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
JP2006522744A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法
AU2004234190A1 (en) 2003-04-30 2004-11-11 Merck Frosst Canada Ltd 8-(3-biaryl)phenylquinoline phosphodiesterase-4-inhibitors
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN1618796A (zh) 2003-11-21 2005-05-25 吉林省药物研究所 4，5－二取代－2－（1－取代－1h－吡咯－2－基）－噻唑衍生物
ES2360222T3 (es) 2003-12-24 2011-06-02 Biota Scientific Management Pty. Ltd. Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial.
GB0402496D0 (en) 2004-02-04 2004-03-10 Argenta Discovery Ltd Novel compounds
JP4853284B2 (ja) 2004-03-05 2012-01-11 大正製薬株式会社 チアゾール誘導体
GB0406279D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
GB0406280D0 (en) 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Chemical compounds
US20070293482A1 (en) 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
KR20070002085A (ko) 2004-04-07 2007-01-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105765A1 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1742627A4 (en) * 2004-05-06 2009-08-26 Plexxikon Inc PDE4B HEMMER AND ITS USE
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2006014361A1 (en) * 2004-07-02 2006-02-09 Genentech, Inc. Inhibitors of iap
AU2005272815A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of ATP-utilizing enzymes
JP2008510734A (ja) * 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
MX2007003325A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
EP1830837B1 (en) * 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AU2005286728A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
JPWO2006051704A1 (ja) * 2004-11-15 2008-05-29 大正製薬株式会社 イミン化合物
CN1834095B (zh) * 2005-03-18 2011-04-20 中国科学院上海药物研究所 一类非核苷类抗病毒抑制剂及其制备方法和用途
KR20080019213A (ko) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
AU2006244068B9 (en) 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
JPWO2006137527A1 (ja) 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
SI1921077T1 (sl) 2005-08-02 2017-11-30 Kyowa Hakko Kirin Co., Ltd. Sredstvo za zdravljenje in/ali preprečevanje motnje spanja
JP2007126454A (ja) 2005-10-06 2007-05-24 Taisho Pharmaceut Co Ltd アニリド誘導体
TWI417096B (zh) 2006-01-25 2013-12-01 Synta Pharmaceuticals Corp 用於發炎及免疫相關用途之苯基及吡啶基化合物

Also Published As

Publication number Publication date
JP2010504348A (ja) 2010-02-12
RU2009114857A (ru) 2010-10-27
CN101516877A (zh) 2009-08-26
US20100029718A1 (en) 2010-02-04
KR20090053923A (ko) 2009-05-28
EP2066664A1 (en) 2009-06-10
CA2662574A1 (en) 2008-03-27
AU2007299870A1 (en) 2008-03-27
BRPI0718509A2 (pt) 2015-09-29
JP5351025B2 (ja) 2013-11-27
WO2008036715A1 (en) 2008-03-27
CN101516877B (zh) 2013-09-11
US8236835B2 (en) 2012-08-07

Similar Documents

Publication Publication Date Title
MX2009003080A (es) Compuestos organicos heterociclicos.
TW200942534A (en) Organic compounds
WO2007143597A3 (en) Organic compounds
MX2009006728A (es) Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
WO2009156484A3 (en) Organic compounds
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
UA94749C2 (en) Benzimidazole modulators of vr1
UA100007C2 (ru) Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
PH12013500848A1 (en) Trpv1 antagonists and uses thereof
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MX2009006473A (es) Inhibidores de receptor vainilloide de bencimidazol.
IN2012DN01913A (es)
SG158091A1 (en) Imidazoazepinone compounds
TN2010000378A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase
TN2010000598A1 (en) Organic compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal